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An enriched population of human natural killer (NK) cells was obtained by density 
gradient centrifugation. The cytotoxic activity of these cells was enhanced by pretreat- 
ment with human leukocyte interferon (IF), and the metabolic requirements of this 
enhancement were examined. Augmentation of NK activity was initiated in a rapid, 
temperature-independent manner, requiring only a lo- to 15min exposure to IF. and 
occurred at either 4 or 37°C. Increased activity of the IF-treated NK effector cells was 
consistently observed after only 30 min of contact with target cells. Augmentation was 
inhibited by prior treatment of NK effector cells with actinomycin D (AD), but treatment 
with AD after 1 hr of IF treatment did not inhibit the IF-mediated increase in cytotoxic- 
ity, suggesting that the RNA species required for enhancement are synthesized within 1 
hr of cell-IF interaction. Protein synthesis was required for at least 1 hr following 
cell-IF interaction, as shown by the ability of emetine and puromycin treatments to 
abrogate increased NK cell activity. Binding of IF to cells was independent of protein 
synthesis. IF-induced enhancement was unaffected by incubation of effector cells with 
mitomycin C either before or after IF treatment, indicating that IF acts primarily upon a 
population of preexisting cells of lower NK activity. 
INTRODUCTION 
The antiviral properties of the glycoproteins called the interferons have been the 
subject of numerous investigations since their discovery over two decades ago (I). 
Only in recent years has come the recognition that interferon (IF)* can also exert a 
variety of significant effects upon immunological functions. One of these effects is 
the enhancement by IF of natural killer (NK) cell activity, a lymphocyte-mediated 
cytotoxic reaction against virus-infected or malignantly transformed target cells 
which does not require previous exposure of the effector cells to the targets (2-2). 
The subset of lymphocytes mediating NK activity in man has not been com- 
pletely defined, although a number of methods have been used to further purify 
hNK effector cells. These include enrichment of cells with Fc receptors (6), ad- 
sorption and elution from target cells, and density and velocity fractionation (7). 
Recently, the latter technique has been utilized by Timonen and Saksela (8), who 
devised a density gradient of a colloidal silica medium (Percoll) which permits 
considerable enrichment of NK effector cells. Using a modification of this proce- 
dure, we have obtained a highly enriched population of NK effect-or cells from 
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human peripheral blood. We were thus able to examine the effects of IF upon the 
cells more directly responsible for mediating the NK reaction. 
Interest in the mechanisms of NK ceil activity has been increasing due to its 
potential role in immunologic defense against tumors (9- 14), and self-regulation 
of lymphoid cell functions (15- 17). The antitumor properties of IF are also cur- 
rently under investigation, both in the laboratory and in clinical trials (18). Since 
the ability of IF to act against malignant cells in man may be partially due to its 
enhancement of the NK reaction, it is important to gain greater knowledge of the 
events involved in this enhancement. The cellular and biochemical mechanisms 
associated with IF-mediated augmentation of the NK reaction are still largely 
unknown. 
Although natural cytotoxicity has been observed in both murine and human 
systems, significant interspecies differences exist in its expression. An age-related 
decline in murine NK activity is not paralleled in man (19). While the greatest 
tissue-associated murine NK activity is observed in spleen, in man peripheral 
blood lymphocytes manifest the highest NK activity, and human NK cells are 
significantly more radiosensitive than their murine counterparts (7). We thus ex- 
amined IF-enhanced NK activity in the human to compare the biochemical re- 
quirements of this enhancement to those in the mouse (20,21). The present study 
extends previous investigations in which total human peripheral blood mononu- 
clear cells (PBMC) were used (22) by utilizing a highly enriched population of NK 
effector lymphocytes. Since total PBMC contain cell populations which can them- 
selves modify NK activity, it is important to determine the effects of IF on 
purified NK effector cell populations. 
MATERIALS AND METHODS 
Lymphocyte separation. PBMC were separated from heparinized venous blood 
of healthy adult donors by Ficoll-Hypaque density gradient centrifugation (23). 
Cells were washed three times with 0.85% NaCl and resuspended in RPM1 1640 
culture medium containing 5% fetal calf serum, fresh glutamine (300 pg/ml), and 
antibiotics (hereafter referred to as complete medium, CM). Cells were depleted 
of monocytes by incubation on a column of Sephadex G-10 (Pharmacia Chemi- 
cals, Piscataway, N.J.) according to the method of Ly and Mishell (24). Cells 
eluted from this column contained < 1% esterase-positive monocytes. 
Percoll enrichment of NK effector cells. Discontinuous density gradients of 
Percoll (Pharmacia) were prepared as described by Timonen and Saksela (8) with 
slight modifications. Percoll was diluted to various concentrations in RPM1 1640 
medium, and 2-ml volumes of each fraction were layered into a 15 x 10.5mm glass 
test tube. These gradients consisted of six fractions, starting with 50% Percoll 
(fraction 5) and decreasing by 2.5% increments to 37.5% (fraction 0). Monocyte- 
depleted lymphocytes were layered on top of this gradient and centrifuged at 300 g 
for 45 min at 22°C. Fractions were collected with a Pasteur pipet and washed twice 
in CM. 
Results of 18 experiments consistently demonstrated the highest NK activity in 
fractions 0 and 1 (Fig. 1). We then employed a simpler, three-layer gradient to 
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FIG. 1. Density gradient separation of NK cells. Monocyte-depleted lymphocytes were layered onto 
a gradient of six Percoll fractions. Fractions O-5 represent 37.5, 40.0, 42.5, 47.5. and 50% Percoll, 
respectively. Results represent mean t SE of experiments using 18 different donors. 
enrich for NK effecters in subsequent experiments. This gradient consisted of 
4-ml layers of 40,45, and 50% Percoll in a 15 x 105mm glass tube. Centrifugation 
was performed as above, and the cells from the 40% interface were used as NK 
effector cells in all subsequent experiments. Cells found at this 40% interface were 
shown in eight experiments to possess NK activity not significantly different from 
cells found at the fraction 0 interface in the six-layer gradient. 
NK target cells. The human leukemic cell line, K562, recently shown to be of 
probable erythroid origin (25), was used as targets for NK cells. K562 cells pas- 
saged 48 hr prior to the day of use were labeled by the addition of 200 ,uCi of Na, 
Wr04 (200-500 Ci/g, New England Nuclear, Boston, Mass.) to 5 x 106: K562 
cells in 0.8 ml CM. The cells were incubated for 1 hr at 37°C in a humid 5% CO,, 
95% air atmosphere, with frequent shaking. Cells were then washed three times 
with CM and resuspended to a concentration of 1Ojiml. 
NK cytotoxicity assay. NK activity was measured by a 4 hr direct SLCr-release 
assay, except where noted. The effector-to-target ratio was 20: 1 in all experiments 
unless stated otherwise, as this ratio was selected from a number of previously 
tested ratios as providing optimal results. Thus, 2 x lo5 viable effector cells were 
added to IO4 labeled viable target cells in triplicate cultures of 0.2 ml each in 
V-bottom microtitration plates (Costar, Cambridge, Mass.). Plates were centri- 
fuged at 40g for 5 min, then incubated 4 hr at 37°C in a humid 5% CO.), 95% air 
atmosphere. At the completion of incubation, plates were centrifuged at 700g for 
5 min, and 0.1 ml of culture supernatant was harvested from each well and 
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counted in a Packard Model 5320 gamma spectrometer. Percentage cytotoxicity 
was calculated as 
percentage cytotoxicity = 
experimental release - spontaneous release 
total counts - spontaneous release 
x 100, 
where spontaneous release represents counts released from wells containing IO4 
target cells alone, and total counts represents counts contained in an aliquot of 104 
target cells. 
IF augmentation of NK effector cells. NK effector cells, isolated as described 
above, were suspended at a cell density of 5 x lo6 cells/ml in CM containing 500 
U/ml of partially purified human leukocyte IF (sp act 6.3 x 104 units/mg protein, a 
kind gift from Parke-Davis and Co., Detroit, Mich.). Cells were incubated with 
IF for 1 hr at 37°C in a humid 5% COz, 95% air atmosphere, except where noted, 
and were washed prior to use. 
Drug treatments. Cells were incubated at a density of 5 x lo6 cells/ml in CM 
containing the stated concentrations of drugs, at 37°C. All incubations with drugs 
lasted 45 min except incubations with puromycin (PM), which were maintained for 
1 hr. Cells were washed following treatment unless stated otherwise. The drugs 
used, mitomycin C (MC), actinomycin D (AD), emetine HCI (EM), and puromy- 
tin (PM), were all purchased from Sigma Chemical Company, St. Louis, Mis- 
souri. None of the drug treatments decreased cell viability as determined by 
trypan blue exclusion. All drug solutions were prepared fresh on the day of use. 
Assays of DNA, RNA, and protein synthesis. Following drug and/or IF treat- 
ments, aliquots of each experimental effector cell suspension were used to simul- 
taneously assay NK activity and DNA, RNA, or protein synthesis. The latter 
were quantitated via the incorporation of [3H]thymidine, [3H]uridine, and 
[3H]leucine, respectively. All radiochemicals were purchased from New England 
Nuclear, Boston, Massachusetts. In these assays, 5 fig of phytohemagglutinin-P 
(PHA, Difco, Labs, Detroit, Mich.) were added to each culture well. Control 
cultures without PHA were included in each experiment, and although the abso- 
lute incorporation of radiolabel was consistently greater in the mitogen-stimulated 
cultures, the qualitative pattern of the drug effects on stimulated and unstimulated 
cultures was comparable. 
To assay DNA synthesis, 2 x lo5 cells were incubated in a volume of 0.2 ml of 
CM in triplicate in round-bottom microtitration plates (Costar). Cultures were 
incubated at 37°C for 72 hr; 18 hr prior to harvesting, 2 @i of [3H]thymidine (6.7 
Cilmmol) were added to each well. Cultures were harvested onto glass fiber filters 
using an automated cell harvester. Filters were dried and placed in scintillation 
vials containing 1 ml of Hydrofluor (National Diagnostics, Somerville, N.J.). Vials 
were counted in a Beckman Model LS 7000 scintillation counter. 
To assay RNA synthesis, cells were plated as described above and cultured for 
18 hr in the presence of [3H]uridine (37.6 Wmmol) at 1 &i/well. The cells were 
harvested on glass fiber filters as above and acid-precipitable material was pre- 
cipitated with 6% sulfosalicylic acid. Filters were dried and counted as above. 
To assay protein synthesis, cells in CM were centrifuged following removal of 
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aliquots for NK assay, and resuspended in leucine-free minimal essential medium 
containing 5% fetal calf serum. Cells were plated as above and cultured for 4 hr in 
the presence of 2 $Zi of [3H]leucine (55.9 Ci/mmol) per well. Cells were harvested 
and acid-precipitable material counted as previously described. 
Statistical analysis ofdata. Statistical significance of the effects of separate and 
combined drug and IF treatments upon NK cytotoxicity was determined by 
analysis of variance, using a computer program provided by the Biostatistics 
Computing Center of The University of Michigan, Ann Arbor, Michigan. 
RESULTS 
Temperature and time dependence of IF-induced NK augmentatiorl. To deter- 
mine the effects of temperature of incubation and duration of IF treatment upon 
IF-induced NK augmentation, Percoll-enriched NK effector cells were treated 
with 500 U/ml of IF at 4 or 37°C for varying periods of time. The results, presented 
in Fig. 2, show that IF-induced augmentation occurs rapidly at either 4 or 37°C. 
although a slightly greater enhancing effect is seen when cells are incubated with 
IF at 37°C. Statistically significant (P = 0.05) enhancement is observed after only 
15 min of IF treatment. IF thus seems to interact quickly with NK effector cells, 
even at a nonphysiologic temperature. 
To determine the kinetics of IF enhancement of NK activity, effector cells were 
incubated with 500 U/ml of IF for 1 hr at 37°C. Cells were then washed, added to 
labeled target cells, and percentage cytotoxicity was determined at 0.5, 1.2.4, and 
8 hr. Results, shown in Fig. 3, demonstrate that the percentage cytotoxicity of 
IF-treated cultures is consistently greater than untreated cultures, and the differ- 
ence is apparent after only 15 min of IF interaction with target cells. However, 
statistically significant differences were reached only after 2 hr. 
Effects of MC on IF-induced NK augmentution. DNA synthesis of Percoll- 
enriched NK effector cells was inhibited by treatment with 0.5, 5. or 50 pg/ml of 
MC for 45 min at 37°C either before or after IF treatment. Cells were then tested 
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FIG. 2. Effect of temperature on IF augmentation of NK activity. NK cells were treated with 500 
U/ml of IF for 0, 15, 30,45, or 60 min at 4 or 37°C. Results represent mean rt SE of experiments using 
three different donors. 
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FIG. 3. Kinetics of IF augmentation of NK activity. NK cells were incubated with or without 500 
U/ml of IF for 1 hr. Percent cytotoxicity was determined at 0.5, 1, 2, 4, and 8 hr after addition of labeled 
target cells. Results represent mean f  SE of experiments using three different donors. 
for NK activity and ability to incorporate [3H]thymidine. Results are presented in 
Fig. 4. A dose of MC (50 &ml) capable of 93-96% inhibition of [3H]thymidine 
incorporation (Figs. 4B and D) given either before (Figs. 4A and B) or after (Figs. 
4C and D) IF treatment has no significant effect upon the extent of IF-induced 
augmentation. It appears from these findings, as well as from the temperature- 
independence of IF effects upon NK activity and the expression of these effects 
within a brief period, that IF-induced augmentation of NK cells does not require 
cellular proliferation or DNA synthesis. 
Effects of AD on IF-induced NK augmentation. Effector cell RNA synthesis 
was inhibited by treatment of cells with 0.025, 0.25, or 2.5 pg!rnl of AD for 45 min 
at 37°C either before or after IF treatment. Effects of AD on NK activity are shown 
in Figs. 5A and C. Effects of AD on [3H]uridine incorporation are shown in Figs. 
5B and D. In Fig. 5A, it can be seen that incubation of cells with AD before IF 
treatment not only decreases spontaneous NK activity but also inhibits the en- 
hancement of NK activity induced by IF treatment. Results presented in Fig. 5C 
demonstrate that treatment with AD following 1 hr of incubation with or without 
IF decreases IF-enhanced NK activity in a dose-dependent manner. However, 
AD, even at high concentrations, is unable to abrogate IF-induced enhancement 
which remains significantly elevated when compared to spontaneous NK activity. 
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FIG. 4. Effects of mitomycin C on IF augmentation of NK activity. NK cells were treated with MC 
either before (A, B) or after (C, D) treatment with IF. B and D represent mean of results obtained with 
both IF-treated and untreated cells, since IF treatment did not alter uptake of [3Hjthymidine. In both A 
and C, neither NK activity nor the extent of IF-induced augmentation of activity were significantly 
reduced by MC treatment (P > 0.05). Results represent mean + SE of experiments using four different 
donors. 
The results imply that RNA synthesis is required in the initial interaction of 
effector cells with IF, but after 1 hr of cell-IF contact, RNA synthesis is no 
longer necessary. 
Effects of EM ON IF-induced NK augmentatiotz. Protein synthesis by NK ef- 
fector cells was inhibited irreversibly by treatment with EM for 45 min at 37°C 
either prior to or following IF treatment. Results of cytoxicity assays are shown in 
Figs. 6A and 6C; incorporation of [3H]leucine by cells is shown in Figs. 63 and D. 
Treatment with EM greatly decreases spontaneous NK activity, and blocks IF- 
induced augmentation of activity, whether given before (Fig. 6A) or after (Fig. 6C) 
IF treatment. 
Effects of PM on ZF-induced NK augmentation. Protein synthesis in effector 
cells was inhibited reversibly by treatment with 0.25, 2.5, or 25 pg/ml of PM for 1 
hr at 37°C either before or after IF treatment. Results of NK assays are presented 
in Figs. 7A and C; [3H]leucine uptake is shown in Figs. 7B and D. Figure 7A 
demonstrates that treatment with PM before IF treatment does not significantly 
affect the extent of IF-mediated NK enhancement. However, the inhibitory action 
of PM on protein synthesis is easily reversed after the drug is washed out, as seen 
in Fig. 7B. Therefore, when PM was given following IF treatment (Figs. 7C and 
D), PM was not washed out prior to assay. In previous experiments we found that 
when IF and PM are added to cells simultaneously and washed out after 1 hr, the 
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FIG. 5. Effects of actinomycin D on IF augmentation of NK activity. NK cells were treated with AD 
either before (A, B) or after (C, D) treatment with IF. B and D represent mean of results obtained with 
both IF-treated and untreated cells, since IF treatment did not alter uptake of rH]uridine. (A) Both 
NK activity and the extend of IF-induced augmentation of activity were significantly decreased by AD 
treatment given prior to IF treatment (P < 0.01). (C) Neither NK activity nor the extent of IF-induced 
augmentation of activity were significantly decreased by PM treatment given following 1 hr of IF 
treatment (P > 0.05). Results represent mean f  SE of experiments using 4 different donors. 
IF-induced augmentation of NK activity is as great as when cells are treated with 
IF alone. The binding of IF to NK cells thus appears to be independent of protein 
synthesis. If PM treatment is given after IF treatment, IF-mediated augmentation 
is significantly decreased, as is the ability of cells to incorporated [3H]leucine. 
Thus if protein synthesis is inhibited after the IF augmentation process has begun, 
IF-mediated enhancement of NK activity cannot proceed. Kinetic experiments 
are currently underway to determine at what point in the 4 hr NK assay protein 
synthesis can be blocked without blocking the IF augmentation process. 
DISCUSSION 
IF-induced augmentation of human NK activity occurs rapidly, within minutes 
of cell-IF interaction, and is independent of temperature. Similar independence 
from temperature is seen in the induction of the antiviral state by IF (26,27). Thus 
a brief interaction of cells and IF seems sufficient to initiate both induction of 
antiviral activity and enhancement of NK activity. Augmented NK activity fol- 
lowing removal of IF from culture medium is evident by 30 min of effector 
cell-target contact, and is fully expressed by 2 hr. 
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FIG. 6. Effects of emetine on IF augmentation of NK activity. NK cells were treated with EM either 
before (A, B) or after (C, D) treatment with IF. B and D represent mean of results obtained with both 
IF-treated and untreated cells, since IF treatment did not alter uptake of j3H]leucine. In both A and C. 
NK activity and the extent of IF-induced augmentation of activity were significantly decreased by AD 
treatment (P < 0.01). Results represent mean k SE of experiments using four different donors. 
New DNA synthesis is not necessary for the enhancement process, as en- 
hancement of NK cells by IF is not blocked by MC added either before or after IF 
treatment. Ortaldo et al. (22), using unfractionated PBMC, also found that treat- 
ment of effector cells with MC prior to IF treatment did not reduce the resulting IF 
enhancement of activity. Using highly enriched NK cells, our results confirm this 
finding and further show that MC given after IF treatment is also ineffective in 
reducing enhancement of activity. Studies using a single-cell binding assay to 
measure NK activity have demonstrated that pretreatment of effecters with IF 
does not alter the number of effector-target conjugates formed, but increases the 
proportion of conjugates containing dead targets (28, 29). These results support 
the concept that IF does not enhance the NK reaction by causing proliferation of 
mature effector cells, but acts either (a) by recruiting mature NK cells from an 
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FIG. 7. Effects of puromycin on IF augmentation of NK activity. NK cells were treated with PM 
either before (A, B) or after (C, D) treatment with IF. B and D represent mean of results obtained with 
both IF-treated and untreated cells, since IF treatment did not alter uptake of [3HJleucine. (A) Neither 
NK activity nor the extent of IF-induced augmentation of activity were significantly decreased by PM 
treatment given prior to IF treatment (P > 0.05). (C) Both NK activity and the extent of IF-induced 
augmentation of activity were significantly decreased by PM treatment given following 1 hr of IF 
0.01). Results represent mean f  SE of experiments using four different donors. 
existing “pre-NK” cell population, or (b) by raising the cytotoxic efficiency of 
mature NK cells. Our present results are consistent with, but do not allow us to 
discriminate between, these two mechanisms, and it is possible that both contrib- 
ute to IF-induced enhancement of NK cells. 
IF-induced NK augmentation is dependent upon de nova RNA synthesis during 
initial cell-IF contact, since treatment of NK effector cells with AD before IF 
treatment results in marked inhibition of the IF-induced increase in NK activity. 
When cells are incubated with IF for’i hr prior to treatment with AD, however, no 
significant decrease in the augmentation is seen, indicating that the necessary 
RNA is synthesized within 1 hr of cell-IF contact. Our results parallel those of 
Ortaldo et al. (22); however, these investigators found that incubation of cells with 
IF for approximately 6 hr was required to block subsequent inhibition of NK 
enhancement by AD. Since these earlier experiments used total PBMC and fibro- 
blast or P-IF, differences in results may be attributed to differences between the 
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actions of leukocyte or a-IF and purified NK cells as used in the present studies. 
Alternatively, monocytes present in unfractionated PBMC, known to decrease 
NK activity, may antagonize the IF enhancement process, thus increasing the 
time required. 
Effects of the protein synthesis inhibitors EM and PM clearly indicate that 
protein synthesis is a basic requirement of IF-induced enhancement of NK cells. 
Our findings in this regard are in agreement with those of Ortaldo et al. (22), who 
also found that pretreatment of effector cells with EM abrogates subsequent IF 
enhancement. By treating effector cells with EM following 1 hr of IF treatment. 
we additionally demonstrate that protein synthesis is required for at least 1 hr 
following removal from IF-containing medium. Binding of IF to cells, however, 
seems independent of protein synthesis. A requirement for protein synthesis is also 
a feature of IF-mediated induction of viral resistance (18), and specific enzymatic 
activities are known to be induced in IF-treated cells concomitant with the in- 
duction of viral resistance (30). 
Although a number of similarities exist in the metabolic requirements for IF- 
mediated enhancement of NK activity and induction of viral resistance, indicating 
that the two processes may occur via related biochemical events, it is unlikely that 
they possess identical mechanisms. Whereas the present study has shown that 
IF-mediated augmentation of NK cells is essentially complete by 60 min, the 
antiviral state is not usually conferred upon cells until 6- 12 hr after exposure to IF 
(31). Thus, it is probable that the specific RNA and protein species necessary for 
development of increased NK activity and viral resistance differ, as well as the 
cell populations affected. 
A number of specific proteins could be involved in the enhancement of NK cell 
reactivity induced by IF. Treatment of human ftbroblasts with IF induces the 
synthesis of at least 12 polypeptides (32), and recent evidence implies that serine- 
dependent proteases are necessary to the NK reaction (33), along with an intact 
secretory apparatus (34). It is conceivable that IF could enhance NK activity by 
increasing the rate of synthesis or activity of proteins involved in the cytotoxic 
event. 
Alternatively, IF could enhance NK activity in a less direct manner, perhaps by 
the induction of one or more lymphokines which are themselves able to stimulate 
NK activity. It has recently been shown that the T-cell growth factor, 
interleukin-2 (IL-2), increases the growth and cytotoxic activity of murine NK 
cells in culture (35). IF may allow NK cells to bind greater amounts of IL-2, or 
IF-augmented NK cells may secrete IL-2. 
IF may also alter membrane receptors or target recognition sites on N K effector 
cells. IF appears to induce increased expression of the murine H-2 and human 
HLA antigens on cell surfaces (18), and IF may affect the expression or configu- 
ration of NK-specific structures on the effector cell membrane. 
The present study has defined the metabolic requirements of the augmentation 
by IF of a highly enriched population of NK effector cells. It is evident, however, 
that much remains to be determined about the molecular mechanisms by which IF 
modulates the NK reaction. Our data strongly support the concept that IF acts 
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upon a preexisting population of NK cells to increase their activity, rather than by 
causing their proliferation. This activation occurs rapidly, is temperature inde- 
pendent, and requires de ~OVO RNA and protein synthesis. Proteins involved in 
the augmentation process may include cytotoxic proteins, lymphokines, or effec- 
tor cell recognition structures. We are currently investigating these possibilities to 
gain increased insight into the cellular and molecular events associated with IF- 
mediated NK cell activation. 
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